Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AZD1390

Small molecule · Inhibitor of ATM · developed by AstraZeneca

Phase 2/3 Most advanced trial
1 Registered trials

What is AZD1390?

AZD1390 is an orally bioavailable ATM kinase inhibitor that prevents DNA damage checkpoint activation and disrupts DNA damage repair, inducing tumor cell apoptosis. It hypersensitizes tumors to chemo/radiotherapy and crosses the blood-brain barrier. It is studied in glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
ATM
Mechanism
Inhibitor of ATM
Pathways
DNA damage checkpoint, DNA damage repair, apoptosis
Therapy area
Oncology
Developer
AstraZeneca
In trials of
BHVN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
CI43QFE22O

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03970447 Phase 2/3 Glioblastoma Recruiting BHVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.